Rituximab Therapy for Severe Refractory Chronic Henoch-Schönlein Purpura
Document Type
Article
Publication Date
2009
Abstract
To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
Repository Citation
Donnithorne, K. J.,
Atkinson, T. P.,
Hinze, C. H.,
Nogueira, J. B.,
Saeed, S. A.,
Askenazi, D. J.,
Beukelman, T.,
& Cron, R. Q.
(2009). Rituximab Therapy for Severe Refractory Chronic Henoch-Schönlein Purpura. Journal of Pediatrics, 155 (1), 136-139.
https://corescholar.libraries.wright.edu/pediatrics/517
DOI
10.1016/j.jpeds.2008.12.049
PMCID
19559299
